Pieris Pharmaceuticals
Developing Anticalin® product candidates to help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.
Pieris has become a publicly traded company on December 18, 2014 (NASDAQ:PIRS).
- CEO Stephen S. Yoder, J.D.
- Industry Biotech
- History IPO